8-K: Polomar Health Services Enters Exclusive Distribution Agreement with ForHumanity Health for Inhalable Medications

Polomar Health Services has signed an agreement granting ForHumanity Health exclusive marketing rights for its inhalable sildenafil and sumatriptan products, aiming to boost revenue through a strategic partnership.

Summary

• Polomar Health Services, Inc. has entered into a Product Fulfillment and Distribution Agreement with ForHumanity Health, Inc. and Island 40 Group, LLC.
• The agreement grants ForHumanity exclusive marketing rights for Polomar's inhalable sildenafil and sumatriptan through September 30, 2025.
• Polomar will handle prescription fulfillment through its subsidiary, Polomar Specialty Pharmacy, LLC.
• Island 40 Group, LLC will provide account management services.
• The initial term of the agreement is three years, with potential renewals based on revenue targets.
• Polomar receives a guaranteed payment of $750,000 for the initial exclusivity period.
• Exclusivity can be extended to March 30, 2026, if ForHumanity generates at least $1,500,000 in sales revenue for Polomar this year.
• Further exclusivity extensions are tied to ForHumanity meeting increased revenue goals.
• Minimum average annual gross revenues received by PMHS from FHH during the Initial Term must be not less than $3,000,000 for the agreement to automatically renew for an additional five-year term.
• Minimum average annual gross revenues received by PMHS from FHH during the 1st Renewal Term must be not less than $6,000,000 for the agreement to automatically renew for an additional five-year term.
• If FHH meets or exceeds its Exclusivity Goal, then this Agreement shall continue to renew and for additional five (5) year terms unless otherwise terminated pursuant to the terms hereof.
• The agreement may be terminated upon ninety (90) days written notice of either Party to the other Party, if gross revenues (Revenues) from FHH to PMHS per month are less than $100,000 per month after the month ending February 2026, or for gross negligence or gross misconduct by either Party, if the negligence or misconduct is not cured within 30 days after receipt of notice from the non-breaching Party.

Sentiment

Score: 7

Explanation: The document presents a positive outlook due to the exclusive distribution agreement and potential revenue growth. However, risks associated with forward-looking statements and reliance on a partner's performance temper the overall sentiment.

Positives

• Polomar secures a guaranteed payment of $750,000 for granting initial exclusivity.
• The agreement provides potential for increased revenue through sales-based exclusivity extensions.
• Polomar retains responsibility for prescription fulfillment, leveraging its existing pharmacy subsidiary.
• The partnership allows Polomar to expand its market reach through ForHumanity's marketing efforts.
• The agreement includes potential renewals for additional five-year terms based on meeting revenue targets.
• FHH shall make a one-time advance payment upon execution hereof to PMHS in the amount of $250,000 to secure the exclusivity granted herein above.

Negatives

• The agreement includes termination clauses if monthly gross revenues from FHH to PMHS are less than $100,000 after February 2026.
• Polomar's revenue is dependent on ForHumanity's marketing effectiveness and sales performance.
• The agreement contains sales of any Dry Inhalables that shall not be subject to the Product Exclusivity provisions herein above: i)sales to clinics or physician practices; and ii)sales to governmental agencies.

Risks

• The success of the agreement depends on ForHumanity's ability to effectively market the licensed medications.
• The agreement's renewal is contingent on meeting specific revenue targets.
• The forward-looking statements are subject to risks and uncertainties, including the risk that the previously licensed intellectual property may not be granted the pending patents.
• There is a risk related to the ability to integrate the ForHumanity telemedicine network into the existing Polomar business and realize the benefits of the Agreement.

Future Outlook

The company anticipates increased revenue and customer value through the partnership with ForHumanity, leveraging their telemedicine network and marketing capabilities. The agreement's success hinges on meeting revenue targets for exclusivity extensions and renewals.

Management Comments

• Management believes forward-looking statements are based upon reasonable assumptions but involve risks and uncertainties.
• Management cautions investors not to place undue reliance on forward-looking statements.

Industry Context

The agreement reflects a trend in the pharmaceutical industry towards strategic partnerships to expand market reach and leverage specialized marketing capabilities. Companies are increasingly focusing on exclusive distribution agreements to maximize the value of their products.

Comparison to Industry Standards

• Exclusive distribution agreements are common in the pharmaceutical industry, with terms varying based on product type, market size, and revenue potential.
• Comparable agreements often include guaranteed minimum payments, sales-based exclusivity extensions, and renewal clauses tied to performance metrics.
• The revenue targets and exclusivity terms in this agreement appear to be within industry norms for similar pharmaceutical products.

Stakeholder Impact

• Shareholders may benefit from potential revenue growth and increased market presence.
• Employees at Polomar Specialty Pharmacy, LLC will be involved in fulfilling prescriptions.
• Customers may have increased access to inhalable sildenafil and sumatriptan through ForHumanity's marketing efforts.
• Suppliers to Polomar may see increased demand for raw materials and components.

Next Steps

• ForHumanity will begin marketing Polomar's inhalable sildenafil and sumatriptan products.
• Polomar will fulfill valid prescriptions through its subsidiary.
• The companies will work towards integrating ForHumanity's telemedicine network into Polomar's business.
• The parties will utilize their best efforts to execute a definitive joint venture agreement on or before April 15, 2025.
• ForHumanity must provide a twelve (12) month forecast of sales, by product to IG4, within ninety (90) days of commencement of sales of Polomar products to customers of FHH, and every quarter subsequently so that IG4 can ensure sufficient product availability and supply.

Key Dates